Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Insomniacs are More Likely to Experience Daytime Symptoms Such as Negative Mood, Fatigue
- WESTCHESTER, Ill., June 21 /U.S. Newswire/ -- Persons suffering from insomnia are more likely to experience various daytime symptoms, including a lack of alertness, negative mood and sleepiness, according to a research abstract that will be presented at the 20th anniversary SLEEP meeting of the Associated Professional Sleep Societies APSS...
- Research articles 2006-06-21
- VivoMetrics(R) LifeShirt(R) System to be Utilized Aboard the International Space Station in a Study to Help Improve Astronauts' Quality of Sleep.
- VENTURA, California, February 28 /PRNewswire/ -- - European Space Agency to Fund Researchers in Irish Universities Who Hope to Determine Sleep Quality While in Space VivoMetrics, Inc., in partnership with the University of Limerick and sponsored by the European Space Agency ESA,...
- Research articles 2006-02-28
- Arena issued patent for 5-HT2A receptor modulators.
- Arena Pharmaceuticals, Inc. (San Diego, CA) was granted EP Patent 1558582, entitled "Diaryl and Arylheteroaryl Urea Derivatives as Modulators of the 5-HT2A Serotonin Receptor Useful for the Prophylaxis and Treatment of Disorders Related Thereto," by the European Patent Office. The patent relates to a class of...
- Research articles 2005-12-01
- MayoClinic.com Sleep Center Offers Tips on Achieving Restful Sleep.
- Byline: Mayo Clinic ROCHESTER, Minn., May 10 AScribe Newswire -- Stress. Work. Kids. Managing a household. These are just a few of life's daily obstacles that keep people from getting enough sleep. On top of the tasks that prevent you from going to bed...
- Research articles 2004-05-10
- Insomnia Pill Makers Go After Elderly With New 'Fear of Falling'
- Insomnia Pill Makers Go After Elderly With New 'Fear of Falling'RE: Insomnia Pill Makers Go After Elderly With New 'Fear of Falling'Great analysis, Jim. As for sales reps showing docs this study -- even the headlines -- it may not be kosher according to FDA off-label promotion regulations, if it's...
- Discussion threads 2008-09-12
- Sleeping and the Job
- Even a few nights of poor sleep can have a dramatic impact on your productivity, mood, and overall effectiveness. Learn just how much damage you're doing to your cognitive functioning and your health by not sleeping enough…You'd never show up at the office drunk. Yet you might as well be...
- Articles 2009-03-04
- Sleep Your Way to the Top
- Want to think faster, make better decisions, and get ahead at work? The secret: Get enough sleep.The workplace is perhaps the ultimate obstacle course. And its difficulty level has only increased now that layoffs threaten almost every company and those left remaining are required to do more just to stay...
- Articles 2009-03-16
Additional Resources
- Somaxon Pharmaceuticals, Inc. Initiates Phase III Clinical Trials of SILENOR in Patients with Insomnia; Product Will Be Evaluated in Adult and Elderly Patients with Primary Chronic Insomnia and Transient Insomnia
- SAN DIEGO -- Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and marketing products for the treatment of insomnia and other neuro-psychiatric disorders, today announced the initiation of patient enrollment in the first Phase III clinical trial of SILENORTM doxepin HCl for insomnia. This multi-center, placebo-controlled Phase III...
- Research articles 2005-06-09
- Older Adults With Insomnia Report Falling Asleep Faster With Ramelteon
- Results from a Phase 3 clinical study presented at the 2005 Annual Scientific Meeting of the American Geriatrics Society showed that bedtime administration of ramelteon, an investigational compound currently under review for the treatment of insomnia, significantly reduced time to fall asleep in older adults with chronic insomnia. Additionally,...
- Research articles 2005-05-12
- Insomnia Pill Makers Go After Elderly With New 'Fear of Falling'
- For years, drug companies have tried to expand the range of prescriptions of sleeping pills. They're not just for sleeping any more -- now they're also for avoiding "rebound insomnia" in the elderly, "increased risk of automotive crashes, decreased work performance ... or mood changes," generalized anxiety disorder, and depression....
- Blog posts 2008-09-11
- New Study Showed Ramelteon Helped Adults With Chronic Insomnia Fall Asleep, Sleep Longer
- Ramelteon, a novel investigational compound under review with the FDA for the treatment of insomnia, reduced the time it took to fall asleep and increased total sleep time in adults with chronic insomnia, according to results from a Phase 3 study presented this week at the 19th Annual Meeting of...
- Research articles 2005-06-20
- Insomnia rolls dice on 'Vegas' with tyro.(Insomnia Entertainment)(Brief Article)
- HOLLYWOOD -- "Romeo Must Die" scribe Eric Bernt will make his feature directing bow with "Vegas Baby," produced by Insomnia Entertainment. Insomnia, backed by Station Casinos' Frank and Lorenzo Fertitta as well as Golden Nugget owners Tim Poster and Tom Breitling,...
- Research articles 2004-11-03
- Herzfeld wakes to Insomnia.(John Herzfeld, Insomnia Entertainment )(Brief Article)
- John Herzfeld will write and direct an untitled film that taps into the no-holds-barred world of the Ultimate Fighting Championship. Station Casinos owners Lorenzo and Frank Fertitta, who also own UFC, will exec produce the film via their Insomnia Entertainment banner. Insomnia's...
- Research articles 2004-12-17
- Merck & Co., Inc. and Lundbeck Discontinue Joint Development Program for Gaboxadol, an Investigational Compound for Insomnia
- WHITEHOUSE STATION, N.J. & COPENHAGEN, Denmark -- Merck & Co., Inc., and H. Lundbeck A/S announced today the discontinuation of their joint development program for gaboxadol, an investigational new medicine for the treatment of insomnia currently in Phase III development. Data from recently completed clinical studies suggest that the overall...
- Research articles 2007-03-28
- Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
- BRANFORD, Conn. -- Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 and Phase 2a clinical studies for NG2-73, the Company's lead compound for the treatment of insomnia, were presented today at the American Psychiatric Association APA annual meeting in San Diego. Two Phase 2b clinical studies...
- Research articles 2007-05-23
- Growing Awareness About the Seriousness of Insomnia Drives the Prescription Sleep Aid Market
- Business Editors/Health/Medical Writers PALO ALTO, Calif.--BUSINESS WIRE--April 27, 2004 Increasing awareness levels coupled with new products targeting an underserved patient base are likely to spark dramatic growth in the lucrative insomnia medication market. Currently, prevalence of insomnia is significantly higher than treatment rates. Though there are over 50...
- Research articles 2004-04-27
- Neurogen Proprietary Insomnia Compound Data to Be Presented at Associated Professional Sleep Societies Annual Meeting
- BRANFORD, Conn. -- Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 and Phase 2a clinical studies for NG2-73, the Company's lead compound for the treatment of insomnia, will be presented in three sessions at the SLEEP 2007 Annual Meeting of the Associated Professional Sleep Societies APSS...
- Research articles 2007-06-04
- Insomnia and Antidepressant Sales Give Lie to DTC Myths
- Direct-to-consumer drug advertising has almost no relationship with consumer demand for prescriptions. That is one interpretation of a story in Ad Age showing that scrips for insomnia pills (such as Sanofi-Aventis's Ambien CR) and antidepressants (such as Eli Lilly's Cymbalta) are up, even though advertising in both those categories is...
- Blog posts 2009-03-05
- ROZEREM(TM) (ramelteon) Showed Significant Reduction in Time to Fall Asleep With No Evidence of Rebound Insomnia or Withdrawal Effects
- Results of a sub-analysis from a Phase III clinical study showed that ROZEREMTM ramelteon significantly reduced time to fall asleep in adults with chronic insomnia and showed no evidence of rebound insomnia or withdrawal effects. The results were presented today at the 2006 Annual Meeting of the American Academy...
- Research articles 2006-04-03
- New Study Presented at worldsleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
- What and When Data from a six-month study of ramelteon will be presented in poster format at worldsleep07: The 5th World Congress of the World Federation of Sleep Research and Sleep Medicine Societies to be held in Cairns, Australia September 2-6, 2007. This large clinical study demonstrated that...
- Research articles 2007-08-31
- << Previous
- page 1 of 1
- Next >>
